Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-05-15
1993-04-13
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 23, 514 53, 514 21, 530399, 536 111, 536122, A61K 3702, A61K 3736, A61K 31715
Patent
active
052023117
ABSTRACT:
Methods for stabilizing fibroblast growth factor (FGF) in heat, acid and/or proteolytic environments are provided. Such methods comprise combining or otherwise complexing FGF with a salt of sucrose octasulfate (SOS) and in particular with the aluminum (sucralfate) or potassium salts thereof. The present invention also provides FGF-stable compositions comprising SOS and FGF. Such compositions can be used in the treatment of FGF-responsive diseases including the treatment of wounds and ulcerative conditions of the gastrointestinal tract. The present invention also provides various diagnostic protocols employing SOS as well as diagnostic kits with SOS as a component thereof. Finally, the present invention provides methods of purifying FGF with SOS.
REFERENCES:
patent: 4912093 (1990-03-01), Michaeli
Senoo, et al., Biochemical and Biophysical Research Communications, 151:701-708 (1988).
Szabo, et al., Digestive Diseases and Sciences 34(8):1323 (1989).
Vlodavsky, et al., PNAS (USA), 64:2292-2296 (1987).
Folkman, et al., Amer. J. Pathol. 130:393-400 (1988).
Klagsburn, et al., PNAS 82:805-809 (1985).
Tasman-Jones, et al., The American Journal of Medicine, 86(suppl. 6A):5-9 (1989).
Szabo, et al., The American Journal of Medicine 86 (suppl. 6A):23-31 (1989).
Konturek, et al., The American Journal of Medicine 86 (suppl. 6A):32-37 (1989).
Guslandi, The American Journal of Medicine 86 (suppl. 6A):45-48 (1989).
Shepherd, et al., The American Journal of Medicine 86 (suppl. 6A):49-54 (1989).
Szabo, et al., Proc. Soc. Exp. Biol. Med., 185:493-497 (1987).
Folkman, et al., Science, 235:442-447 (1987).
Connolly, et al., J. Clin. Invest. 84:1470-1478 (1989).
S. Dai, et al., Pediatric Research, 19:916-918 (1985).
D. Gospodarowicz, et al., Proc. Natl. Acad. Sci. USA, 86:7311-7315 (1989).
T. Kurokawa, et al., FEBS Letter 213(1):189-194 (1987).
Y. Shing, et al., Science, 223:1296-1299 (1984).
D. Goaspodarowicz, et al., Journal of Cellular Physiology, 128:475-484 (1986).
P. Kirkegaard, Gastroenterology 85:1277-1283 (1983).
G. Conn, et al., Proc. Natl. Acad. Sci. USA, 87:1323-1327 (1990).
M. Iwane, et al., Biochemical and Biophysical Research Communications, 146(2):470-477 (1987).
N. Ferrara, et al., Biochemical and Biophysical Research Communications 161(2):851-858 (1989).
J. Folkman et al., Science, 243:1490-1493 (1989).
Shing, et al., Analytical Biochemistry, 185:108-111 (1990).
Folkman, et al., Journal of Cell Biology vol. 111, No. 5, p. 223, column 1. abstract 1244 (1990).
Li, W. W. et al., Investigative Ophthalmology & Visual Science, vol. 32 No. 4, p. 955, column 2, abstract 1412-6:45 (1991).
Folkman Moses J.
Shing Yuen
Children's Medical Center Corporation
Conlin David G.
Moezie F. T.
Resnick David S.
Williams Gregory D.
LandOfFree
Stabilized FGF composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized FGF composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized FGF composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1155424